keyword
MENU ▼
Read by QxMD icon Read
search

stage IV melanoma

keyword
https://www.readbyqxmd.com/read/29221650/-immunohistochemistry-using-clone-ve1-is-an-economic-specific-and-sensitive-method-for-detecting-the-presence-of-brafv600e-mutations-in-melanoma
#1
M Etienne, F Oca, D Prunier-Mirebeau, A Croué, L Martin
BACKGROUND: Determination of BRAF mutation status is mandatory in the management of patients with inoperable stage IIIC or stage IV melanoma. Currently, molecular biology (MB) has been validated for detecting the presence of BRAF mutations. OBJECTIVE: To compare the sensitivity, specificity and cost of immunohistochemistry (IHC) (clone VE1) versus BM methods (qPCR and Sanger sequencing). PATIENTS AND METHODS: All the samples for which BRAF mutation status was requested between March 2013 and February 2015 at the cellular and molecular analysis laboratory of the Angers Hospital were included retrospectively and consecutively...
December 5, 2017: Annales de Dermatologie et de Vénéréologie
https://www.readbyqxmd.com/read/29215399/hemorrhage-of-liver-and-bone-metastases-as-a-result-of-rapid-response-to-dual-braf-mek-inhibition-in-metastatic-melanoma-a-case-report
#2
Tine Loyson, Emilie Werbrouck, Kevin Punie, Lawrence Bonne, Vincent Vandecaveye, Oliver Bechter
Combination therapy using a BRAF and MEK inhibitor significantly improves both progression-free and overall survival in patients with BRAF V600-mutated stage IV melanoma. Dual MAPK inhibition achieves an objective response in the majority of patients. We present a case of a woman with BRAF V600E-mutated malignant melanoma and rapidly progressing liver, bone, and lymph node metastases. The patient commenced dabrafenib and trametinib with clinical and biochemical signs of response after 2 days. On day 3 she developed grade 3 liver hemorrhage, which was successfully embolized...
December 5, 2017: Melanoma Research
https://www.readbyqxmd.com/read/29202855/soluble-cd73-as-biomarker-in-patients-with-metastatic-melanoma-patients-treated-with-nivolumab
#3
Silvana Morello, Mariaelena Capone, Claudia Sorrentino, Diana Giannarelli, Gabriele Madonna, Domenico Mallardo, Antonio M Grimaldi, Aldo Pinto, Paolo Antonio Ascierto
BACKGROUND: Nivolumab is an anti-PD1 checkpoint inhibitor active in patients with advanced melanoma and as adjuvant therapy in high-risk metastatic melanoma patients. METHODS: In this single-center retrospective analysis, we investigated the CD73 enzyme activity in patients with metastatic melanoma stage IV and its correlation with the response to nivolumab. The soluble CD73 (sCD73) enzyme activity was measured in the serum of 37 melanoma patients before receiving nivolumab and the Harrel's C index was used to find the best cut-off for this biomarker...
December 4, 2017: Journal of Translational Medicine
https://www.readbyqxmd.com/read/29195664/-actinomycosis-revealed-by-ulceration-of-the-palate-and-gingiva
#4
F Dessirier, J-P Arnault, J Denamps, H Sevestre, C Attencourt, C Lok
BACKGROUND: Actinomycosis is a chronic and extensive granulomatous, bacterial infection. Revelation by oral ulceration is rare. PATIENTS AND METHODS: A 76-year-old patient with diabetes was treated with dabrafenib for stage IV melanoma. A follow-up visit revealed two ulcerated, infiltrated and hyperalgesic lesions of the palate and gingiva. There were no associated signs. The laboratory findings were normal. The possibility of squamous cell carcinoma occurring with BRAF inhibitors was discussed, despite the rarity of such cases in the literature...
November 28, 2017: Annales de Dermatologie et de Vénéréologie
https://www.readbyqxmd.com/read/29187493/braf-nras-and-c-kit-advanced-melanoma-clinico-pathological-features-targeted-therapy-strategies-and-survival
#5
Giovanni Ponti, Marco Manfredini, Stefano Greco, Giovanni Pellacani, Roberta Depenni, Aldo Tomasi, Monia Maccaferri, Stefano Cascinu
BACKGROUND/AIM: The mutational status of stage III and IV melanomas should be recognized in order to allow for targeted therapies. The aim of our study was the characterization of BRAF, NRAS and C-KIT melanoma patients, in order to define their optimal management. PATIENTS AND METHODS: Between 1991 and 2015, 63 mutated melanoma patients were treated and monitored during their diagnostic and therapeutic management at a single institution. RESULTS: BRAF-mutated melanoma patients were the most common, representing 70% of the study population, while NRAS- and C-KIT-mutated melanoma represented 19% and 11% respectively...
December 2017: Anticancer Research
https://www.readbyqxmd.com/read/29185092/analysis-of-tsc1-mutation-spectrum-in-mucosal-melanoma
#6
Meng Ma, Jie Dai, Tianxiao Xu, Sifan Yu, Huan Yu, Huan Tang, Junya Yan, Xiaowen Wu, Jiayi Yu, Zhihong Chi, Lu Si, Chuanliang Cui, Xinan Sheng, Yan Kong, Jun Guo
PURPOSE: Mucosal melanoma is a relatively rare subtype of melanoma for which no clearly established therapeutic strategy exists. The genes of the mTOR signalling pathway have drawn great attention as key targets for cancer treatment, including melanoma. In this study, we aimed to investigate the mutation status of the upstream mTOR regulator TSC1 and evaluated its correlation with the clinicopathological features of mucosal melanoma. METHODS: We collected 91 mucosal melanoma samples for detecting TSC1 mutations...
November 28, 2017: Journal of Cancer Research and Clinical Oncology
https://www.readbyqxmd.com/read/29177265/metastatic-melanoma-response-to-combination-therapy-with-ipilimumab-and-vemurafenib
#7
Christos Sachpekidis, Jessica C Hassel, Antonia Dimitrakopoulou-Strauss
Combination therapies for the treatment of metastatic melanoma are a matter of debate nowadays. We report on a stage IV metastatic melanoma patient with the BRAF V600 mutation and a large tumor burden initially treated with two cycles of ipilimumab. Due to dramatic disease progression, demonstrated on interim 18F-FDG PET/CT, vemurafenib was added in the patient's therapeutical scheme. After completion of the concurrent ipilimumab and vemurafenib administration, a third 18F-FDG PET/CT showed an impressive metabolic remission of the metastatic disease, reflecting the potential role of the modality in treatment response evaluation of melanoma patients receiving combination therapies...
November 27, 2017: Hellenic Journal of Nuclear Medicine
https://www.readbyqxmd.com/read/29177235/metastatic-melanoma-patients-sensitivity-to-ipilimumab-cannot-be-predicted-by-tumor-characteristics
#8
Kara Rossfeld, Erinn M Hade, Alexandra Gangi, Matthew Perez, Emily N Kinsey, Joanna Grabska, Ashley Ederle, Jonathan Zager, April K Salama, Thomas E Olencki, Georgia M Beasley
Immune checkpoint inhibitors have dramatically changed the prognosis for patients with metastatic melanoma. However, not all patients respond to therapy and toxicities can be severe leaving need for reliable clinical predictive markers. Methods: We examined primary tumor characteristics including ulceration, BRAF mutation status, and Breslow depth in patients who subsequently developed stage IV disease and were treated with ipilimumab at 3 institutions. Patients in this study were not treated on clinical trials...
October 2017: International Journal of Surgery. Oncology
https://www.readbyqxmd.com/read/29176861/variables-that-influence-braf-mutation-probability-a-next-generation-sequencing-non-interventional-investigation-of-brafv600-mutation-status-in-melanoma
#9
Maria Rita Gaiser, Alexander Skorokhod, Diana Gransheier, Benjamin Weide, Winfried Koch, Birgit Schif, Alexander Enk, Claus Garbe, Jürgen Bauer
BACKGROUND: The incidence of melanoma, particularly in older patients, has steadily increased over the past few decades. Activating mutations of BRAF, the majority occurring in BRAFV600, are frequently detected in melanoma; however, the prognostic significance remains unclear. This study aimed to define the probability and distribution of BRAFV600 mutations, and the clinico-pathological factors that may affect BRAF mutation status, in patients with advanced melanoma using next-generation sequencing...
2017: PloS One
https://www.readbyqxmd.com/read/29170503/mutational-and-putative-neoantigen-load-predict-clinical-benefit-of-adoptive-t-cell-therapy-in-melanoma
#10
Martin Lauss, Marco Donia, Katja Harbst, Rikke Andersen, Shamik Mitra, Frida Rosengren, Maryem Salim, Johan Vallon-Christersson, Therese Törngren, Anders Kvist, Markus Ringnér, Inge Marie Svane, Göran Jönsson
Adoptive T-cell therapy (ACT) is a highly intensive immunotherapy regime that has yielded remarkable response rates and many durable responses in clinical trials in melanoma; however, 50-60% of the patients have no clinical benefit. Here, we searched for predictive biomarkers to ACT in melanoma. Whole exome- and transcriptome sequencing and neoantigen prediction were applied to pre-treatment samples from 27 patients recruited to a clinical phase I/II trial of ACT in stage IV melanoma. All patients had previously progressed on other immunotherapies...
November 23, 2017: Nature Communications
https://www.readbyqxmd.com/read/29169461/lymphatic-versus-hematogenous-melanoma-metastases-support-for-biological-heterogeneity-without-clear-clinical-application
#11
Gyulnara G Kasumova, Alex B Haynes, Genevieve M Boland
Melanoma demonstrates considerable biological heterogeneity and is associated with several routes of dissemination including lymphatic and hematogenous. Locoregional control via surgery may improve outcomes for patients with limited lymphatic metastases. Once stage IV disease is diagnosed, clinical outcomes are determined by molecular and/or immunologic factors and identification of tumor/microenvironmental features correlating with distant metastases is critical for future prognostic stratification.
December 2017: Journal of Investigative Dermatology
https://www.readbyqxmd.com/read/29164593/immune-correlates-of-clinical-outcome-in-melanoma
#12
REVIEW
Graham Pawelec
Melanoma has long been recognized as a potentially immunogenic tumour, but only recently has it become clear that the reason for this resides in its many UV-induced mutations and expression of multiple autoantigens which can be targeted by the immune system. The first successful applications of immune-based treatments included passive immunotherapy using high-dose IL-2 and/or adoptive transfer of NK-cells, as well as active immunotherapy using whole cell-derived or peptide vaccines. In the intervening decades, it has become clear that these approaches can lead to durable responses in stage III/IV melanoma, and even to functional cures - but only in a vanishingly small fraction of patients...
November 21, 2017: Immunology
https://www.readbyqxmd.com/read/29164492/advanced-melanoma-current-treatment-options-biomarkers-and-future-perspectives
#13
REVIEW
Elisa A Rozeman, Tim J A Dekker, John B A G Haanen, Christian U Blank
Malignant melanoma accounts for the highest number of deaths from skin cancer, and the prognosis of patients with stage IV disease has historically been poor. Novel insights into both mutations driving tumorigenesis and immune escape mechanisms of these tumors have led to effective treatment options that have revolutionized the treatment of this disease. Targeting the MAPK kinase pathway (with BRAF and MEK inhibitors), as well as targeting checkpoints, such as cytotoxic T-lymphocyte associated protein 4 (CTLA-4) or programmed death 1 (PD-1), have improved overall survival in patients with late-stage melanoma, and biomarker research for personalized therapy is ongoing for each of these treatment modalities...
November 21, 2017: American Journal of Clinical Dermatology
https://www.readbyqxmd.com/read/29157311/peripheral-and-local-predictive-immune-signatures-identified-in-a-phase-ii-trial-of-ipilimumab-with-carboplatin-paclitaxel-in-unresectable-stage-iii-or-stage-iv-melanoma
#14
Rahima Jamal, Réjean Lapointe, Eftihia Cocolakis, Paméla Thébault, Shirin Kazemi, Jennifer E Friedmann, Jeanne Dionne, Jean-François Cailhier, Karl Bélanger, Jean-Pierre Ayoub, Huy Le, Caroline Lambert, Jida El-Hajjar, Léon C van Kempen, Alan Spatz, Wilson H Miller
BACKGROUND: Checkpoint blockade with ipilimumab provides long-term survival to a significant proportion of patients with metastatic melanoma. New approaches to increase survival and to predict which patients will benefit from treatment are needed. This phase II trial combined ipilimumab with carboplatin/paclitaxel (CP) to assess its safety, efficacy, and to search for peripheral and tumor-based predictive biomarkers. METHODS: Thirty patients with untreated unresectable/metastatic melanoma were treated with ipilimumab and CP...
November 21, 2017: Journal for Immunotherapy of Cancer
https://www.readbyqxmd.com/read/29152725/regressed-melanocytic-nevi-secondary-to-pembrolizumab-therapy-an-emerging-melanocytic-dermatologic-effect-from-immune-checkpoint-antibody-blockade
#15
Shakuntala H Mauzo, Michael T Tetzlaff, Kelly Nelson, Rodabe Amaria, Sapna Patel, Phyu P Aung, Priyadharsini Nagarajan, Carlos A Torres-Cabala, Adi Diab, Victor G Prieto, Jonathan L Curry
BACKGROUND: Immune checkpoint antibody blockade is an emerging therapeutic option for treating certain cancers including melanoma. This therapy is associated with dermatologic and systemic toxicities, some of which are more severe than others and may require withholding therapy. CASE REPORTS: We report two patients with melanocytic nevi that regressed with pembrolizumab therapy. The first patient had stage IV BRAF K601E/L584F mutant melanoma that developed a regressed melanocytic nevus while being treated with pembrolizumab...
November 20, 2017: International Journal of Dermatology
https://www.readbyqxmd.com/read/29145885/future-perspectives-in-melanoma-research-melanoma-bridge-napoli-november-30th-3rd-december-2016
#16
Paolo A Ascierto, Sanjiv S Agarwala, Gennaro Ciliberto, Sandra Demaria, Reinhard Dummer, Connie P M Duong, Soldano Ferrone, Silvia C Formenti, Claus Garbe, Ruth Halaban, Samir Khleif, Jason J Luke, Lluis M Mir, Willem W Overwijk, Michael Postow, Igor Puzanov, Paul Sondel, Janis M Taube, Per Thor Straten, David F Stroncek, Jennifer A Wargo, Hassane Zarour, Magdalena Thurin
Major advances have been made in the treatment of cancer with targeted therapy and immunotherapy; several FDA-approved agents with associated improvement of 1-year survival rates became available for stage IV melanoma patients. Before 2010, the 1-year survival were quite low, at 30%; in 2011, the rise to nearly 50% in the setting of treatment with Ipilimumab, and rise to 70% with BRAF inhibitor monotherapy in 2013 was observed. Even more impressive are 1-year survival rates considering combination strategies with both targeted therapy and immunotherapy, now exceeding 80%...
November 16, 2017: Journal of Translational Medicine
https://www.readbyqxmd.com/read/29145547/association-of-first-in-class-immune-checkpoint-inhibition-and-targeted-therapy-with-survival-in-patients-with-stage-iv-melanoma
#17
Andrew J Sinnamon, Madalyn G Neuwirth, Phyllis A Gimotty, Tara C Gangadhar, Ravi K Amaravadi, Lynn M Schuchter, Giorgos C Karakousis
No abstract text is available yet for this article.
November 16, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/29135116/serum-s100b-levels-correlate-with-stage-n-status-mitotic-rate-and-disease-outcome-in-melanoma-patients-independent-to-ldh
#18
Athanasios Karonidis, Marina Mantzourani, Helen Gogas, Dimosthenis Tsoutsos
PURPOSE: S100B protein is currently used as an immunohistochemistry marker to confirm melanoma diagnosis in biopsy specimens. Moreover, accumulating evidence supports its potential use as a tumor biomarker in blood. This study aimed to explore the potential uses of serum S100B protein as a biomarker in melanoma patients. METHODS: From 2012 to 2015, 107 sequential patients were diagnosed and treated for melanoma. All patients were tested for serum S100B and lactate dehydrogenase (LDH) at diagnosis and during their regular follow-up...
September 2017: Journal of B.U.ON.: Official Journal of the Balkan Union of Oncology
https://www.readbyqxmd.com/read/29113662/practice-variation-in-sentinel-lymph-node-biopsy-for-melanoma-patients-in-different-geographical-regions-in-the-netherlands
#19
J Verstijnen, S Damude, H J Hoekstra, S Kruijff, A J Ten Tije, W J Louwman, E Bastiaannet, M M Stuiver
BACKGROUND: Due to the lack of solid evidence for treatment benefit of Sentinel Lymph Node Biopsy (SLNB) as part of loco-regional surgical treatment of non-distant metastatic melanoma, there might be variation in surgical treatment strategies in the Netherlands. The objective of the current study was to assess differences in the performance of SLNB, in geographical regions in the Netherlands, of non-distant metastatic melanoma patients (American Joint Committee on Cancer (AJCC) stage I-III)...
December 2017: Surgical Oncology
https://www.readbyqxmd.com/read/29110018/estimation-of-direct-melanoma-related-costs-by-disease-stage-and-by-phase-of-diagnosis-and-treatment-according-to-clinical-guidelines
#20
Alessandra Buja, Gino Sartor, Manuela Scioni, Antonella Vecchiato, Mario Bolzan, Vincenzo Rebba, Vanna Chiarion Sileni, Angelo Claudio Palozzo, Maria Montesco, Paolo Del Fiore, Vincenzo Baldo, Carlo Riccardo Rossi
Cutaneous melanoma is a major concern in terms of healthcare systems and economics. The aim of this study was to estimate the direct costs of melanoma by disease stage, phase of diagnosis, and treatment according to the pre-set clinical guidelines drafted by the AIOM (Italian Medical Oncological Association). Based on the AIOM guidelines for malignant cutaneous melanoma, a highly detailed decision-making model was developed describing the patient's pathway from diagnosis through the subsequent phases of disease staging, surgical and medical treatment, and follow-up...
November 7, 2017: Acta Dermato-venereologica
keyword
keyword
10968
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"